Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
life science investing Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
life science investing VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
life science investing Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
life science investing Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
life science investing Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
life science investing Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
Homerun Resources Inc. Announces Multi-Process Testing Results for Santa Maria Eterna High-Purity Silica Sand Project
